Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (trading symbol: TROV) on March 30, 2020. The filing reports the entry into a Material Definitive Agreement and the unregistered sale of equity securities. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics and Transaction Details
The Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC for a registered direct offering and concurrent private placement.
- Aggregate Gross Proceeds: Approximately $1.0 million (before estimated offering expenses).
- Securities Issued:
- 800,000 shares of Common Stock.
- Series I Pre-Funded Warrants to purchase up to 131,967 shares.
- Series J Warrants to purchase up to 931,967 shares.
- Purchase Price: $1.073 per Share/Series J Warrant combination.
- Series J Warrant Exercise Price: $0.948 per share.
- Series I Pre-Funded Warrant Exercise Price: $0.01 nominal (remainder pre-funded).
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period.
Material Changes and Restrictions
The primary material change is the capital raise described above. As part of the agreement, the Company agreed to a 60-day lock-up period following the closing, during which it will not issue or agree to issue any shares of Common Stock or Common Stock equivalents, subject to certain exceptions.
Outlook, Risks, and Unusual Items
The closing of the offering is subject to the satisfaction of specified customary closing conditions. The Series J Warrants and related shares are being offered pursuant to Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933. The Series I Pre-Funded Warrants and Common Stock are being offered under an effective shelf registration statement (File No. 333-232321).
Investor Verification Checklist
- Verify the actual closing date and confirmation of the $1.0 million gross proceeds.
- Review the definitive transaction documents (Exhibits 10.1, 10.2, and 10.3) for specific warrant terms and adjustment provisions.
- Confirm the impact of the 60-day issuance restriction on future capital raising activities.
- Check subsequent filings for the final number of shares issued and any changes to the offering structure.